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Abstract 
Activating mutations in the core promoter of the TERT gene have been described in many different 
tumor entities. In vitro models showed a two- to fourfold increase in transcriptional activity of the 
TERT promoter through creation of a consensus binding motif for Ets/TCF transcription factors 
caused by these mutations. TERT core promoter mutations are the most common mutations in 
bladder cancer with a frequency between 55.6% and 82.8% described so far, and are independent 
of stage and grade. Since limited data on molecular alterations of early-onset bladder tumors 
exists, we assessed the frequency of TERT core promoter mutations in early-onset bladder cancer. 
Two cohorts of bladder tumors (early-onset patient group; n=144 (age of onset of disease ≤45 
years); unselected, consecutive group; n=125) were examined for TERT core promoter mutations. 
After microdissection and extraction of DNA the corresponding hotspot regions in the TERT core 
promoter were examined by Sanger-sequencing or a SNaPshot approach. A significantly lower 
frequency of TERT core promoter mutations was found in tumors from the early-onset cohort 
compared to the consecutive cohort (57.6% vs. 84.8%, p<0.001). Among the early-onset cohort 
cases younger than the cohort’s median age of 39 years at disease onset showed a significantly 
reduced number of TERT promoter mutations (31/67, 46,3%) than cases aged between 39 and 45 
years (52/77, 67.5%; p=0.012). This association was not found in the consecutive cases. Mutation 
status was independent of tumor stage and grade. We conclude that in tumors from early-onset 
bladder cancer patients TERT core promoter mutations are not as frequent as in bladder tumors 
from consecutive cases, but seem to play an important role there as well. In patients below 39 
years of age TERT core promoter mutations are a more infrequent event, suggesting different 
mechanisms of tumorigenesis in these young patients. 
Key words: bladder cancer, early-onset, TERT, mutation, sequencing. 
Introduction 
The TERT gene encodes the catalytic reverse 
transcriptase subunit of telomerase, a 
RNA-dependent polymerase (ribonucleoprotein 
complex) maintaining telomere length, and 
preventing replicative senescence and genomic 
instability. In stem cells telomerase activity is crucial 
for indefinite replication and the limitless replicative 
potential associated with increased telomerase 
activity is one of the six hallmarks of cancer [1].  
Elements responsible for the regulation of TERT 
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promoter activity are located in a core region that 
includes 330 bp upstream of the ATG start-codon and 
37 bp of exon 2 of the TERT gene. Recently, activating 
TERT core promoter mutations were described in 
familial and sporadic melanoma [2], and since then 
mutations have also been reported in a multitude of 
sporadic tumors [3]. Mutational hotspots are located 
at positions -57, -124 and -146 bp. Mutations at these 
locations lead to nucleotide changes predicted to 
create novel binding motifs for E-twenty-six (Ets) 
transcription factors. In addition, binding motifs for 
the ternary complex factors (TCFs, which are a 
subfamily of Ets transcription factors) Elk1 and Elk4 
are also putatively generated by these alterations. 
Elk1 and Elk4 are downstream targets of BRAF and 
involved in regulating expression of many genes. 
Creation of these de novo Ets/TCF-binding motifs 
leads to an increase in TERT promoter activity and 
gene expression [2]. 
Several studies shed light on the frequency of 
TERT core promoter mutations in urothelial 
carcinoma of the bladder. TERT core promoter 
mutations were found with a frequency up to >80% in 
bladder cancer [4] and are the most common 
mutations in bladder cancer reported to date. 
Interestingly, TERT mutations showed neither a 
correlation to tumor stage or tumor grade, nor to 
disease outcome, but were suggested as a useful urine 
biomarker in the follow-up of bladder cancer patients 
or for proving the urothelial origin in cancers of 
unknown primary [5-7]. In addition, also in rare 
histopathological subtypes of bladder cancer (e.g. 
inverted papilloma, small cell carcinoma) these 
mutations were found but with various frequencies 
[8, 9].  
It is well known that 
exposure to exogenous noxae 
such as amines, cigarette 
smoke, drugs and radiation 
therapy is associated with the 
development of bladder 
cancer, which is typically a 
disease of older people with a 
mean age of diagnosis being between 65 and 70 years 
of age. Only a small fraction (approx. 1.5%) of bladder 
tumors develop before the age of 45 years [10]. These 
tumors represent an interesting cohort to study, since 
tumorigenesis in such “early-onset” bladder tumors 
might be via a different pathway, or they might reveal 
crucial molecular alterations responsible for the 
initiation of urothelial carcinogenesis in general. Since 
only very limited data regarding molecular alterations 
of early-onset bladder tumors exist, we thought it 
reasonable to assess the frequency of TERT core 
promoter mutations in a cohort of such tumors, as this 
might reveal further evidence corroborating a 
different tumorigenesis pathway. 
Methods 
Tissue samples 
Archival formalin-fixed paraffin-embedded 
(FFPE) tumor material from 269 cases acquired 
through transurethral resection was used for the 
study (cohort 1: unselected cases: n=125, cohort 2: 
early-onset-bladder cancer cases (age at time of 
diagnosis ≤45 years): n=144). The tumors were 
classified and staged according to the WHO 
classification of bladder tumors [11] and the current 
AJCC/TNM-classification system [12]. Representative 
images of available histopathological specimens are 
shown in Figure 1. 
Clinicopathological characteristics of the cases 
are shown on Table 1. Prior IRB approval (University 
Hospital Erlangen, Germany) was obtained for the 
study. 
 
 
 
Figure 1: Representative images of 
histopathological specimens (magnification: 
x100). A: Papillary urothelial neoplasia of low 
malignant potential (PUNLMP), TERT: 
wildtype. B: papillary pTa LG tumor, TERT 
wildtype. C: papillary pTa LG tumor, TERT: 
mutation: -124 “G > A”. D: inverted 
papilloma, TERT: wildtype. 
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Table 1: Clinicopathological characteristics of the study cohorts. 
  Consecutive Cohort Early-Onset Tumor Cohort 
Number n=125 n=144 
Age (years) Median: 71 Range:   Median: 39 Range:  
Mean: 70.7 29-94  Mean: 36.6 11-45 
Stage Papilloma n=2  n=5 
Cis n=1  n=0 
Ta n=78  n=83 
T1 n=35  n=14 
≥T2 n=8  n=27 
unknown n=2  n=16 
Grading G1 n=33  n=43 
G2 n=56  n=48 
G3 n=17  n=30 
unknown n=19  n=24 
Gender Male n=95  n=100 
Female n=30  n=24 
unknown n=0  n=21 
 
Microdissection and DNA isolation 
Microdissection and isolation of genomic DNA 
was carried out from FFPE tumor material as 
described previously [13]. In brief, 5 µm thick serial 
sections of the tumor tissue were dewaxed and 
stained with 0.1% methylene blue for 15 seconds. 
Using an inverted microscope the tumor tissue 
(identified through matching with a marked 
H&E-stained section reviewed by an experienced 
surgical pathologist) was scraped off with a sterile 
needle to obtain a tumor cell purity of at least 85%. 
Isolation of genomic DNA from the microdissected 
tumor tissue was performed using the High Pure PCR 
Template Preparation Kit (Roche, Mannheim, 
Germany) according to the manufacturer’s 
instructions. 
TERT promoter mutation analysis 
Mutation analysis of the TERT promoter was 
performed as described recently [2]. In brief, 
Sanger-sequencing of the TERT core promoter was 
carried out using an ABI Prism 3500 Genetic Analyzer 
and the Big Dye Terminator v.1.1 Cycle Sequencing 
Kit (Applied Biosystems, Foster City, Calif., USA) 
according to manufacturer’s instructions. SNaPshot 
assays designed to detect hotspot mutations at 
positions -146, -124 and -57 bp of the TERT promoter 
were used when DNA samples were unsuitable for 
mutation analysis by Sanger sequencing. All primers 
and reaction conditions were described elsewhere in 
detail [2, 14]. 
Statistics 
A two-sided Fisher’s exact test was used to 
evaluate differences in the distribution of TERT 
promoter mutations according to stage, grade or age 
of the patients. Statistical analysis was carried out 
using SPSS version 13.0 (SPSS, Chicago, IL, USA). P 
values less than 0.05 were interpreted as statistically 
significant. 
Results 
All investigated cases were successfully 
analyzed by Sanger sequencing (n=16) or SNaPshot 
analysis (n=253) (Figure 2). Overall, there was a 
significantly lower frequency of TERT promoter 
mutations in the tumors from the early-onset bladder 
cancer patients (83/144, 57.6%) compared to the 
unselected, consecutive cohort (106/125, 84.8%; 
p<0.001; Figure 3). The distribution of the detected 
TERT promoter mutations in our cohorts was very 
similar to the results of previously published bladder 
cancer studies [4, 5] with the majority of the mutated 
cases (92%) carrying -124 G > A (C > T on the opposite 
strand) or -146 G > A mutations (Table 2). In order to 
find a possible age dependency of the occurrence of 
TERT promoter mutations in the tumors from the 
early-onset bladder cancer cohort we stratified this 
cohort against the median age (39 years) of the cohort. 
There was a significantly lower frequency of TERT 
promoter mutations in patients aged <39 years at time 
of first diagnoses compared to patients ≥39years 
(p=0.012; Figure 4). No further association was found 
between TERT promoter mutation and 
clinicopathological characteristics of the tumors. 
 
 
Table 2: Distribution of TERT core promoter mutations in the 
two study cohorts. 
Distance from ATG 
start site (bp) 
Base change Consecutive 
Cohort (n=125) 
Early-Onset 
Tumor Group 
(n=144) 
-57 T > G 6 0 
-124 G > A 75 52 
-124 G > T 2 1 
-146 G > A 22 24 
-57 and -124 T > G and G > A 1 0 
-124 and -146 G > A and G > A 0 5 
-124 and -146 G > T and G > A 0 1 
 
 
Discussion 
In the present study we analysed TERT promoter 
mutations in a large cohort of tumors from patients 
with early-onset disease, and compared mutation data 
to that obtained from an unselected consecutive 
group of bladder tumors. Data from our consecutive 
cohort are in line with previously published studies 
[4-6] and argues for the reliability of the methods used 
and for a non-biased control group. Interestingly, 
there was a significant lower frequency of TERT 
promoter mutations in the tumors from the 
early-onset patients. This fact points to a possible 
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age-dependent occurrence of TERT promoter 
mutations in bladder cancer or a different molecular 
background in early-onset bladder tumors. An 
age-dependent difference in TERT mutation 
frequency in bladder cancer was recently observed in 
two studies. Wu and coworkers found a significantly 
lower mutation frequency in tumors from patients 
aged younger than 50 years [6]. In this study tumors 
from patients below 50 years of age showed a 
mutation frequency of 37.5% vs 59.6% from patients 
≥50 years, however, only a small number of tumors 
from “younger” patients below 50 years of age (n=40) 
was analysed and they did not justify why a cut-off of 
50 years of age was selected. Despite these limitations 
data from Wu and colleagues are in line with the 
results from our study. Wang et al focused on TERT 
promotor mutation analysis of urothelial tumors from 
the upper urinary tract [15]. Within a cohort of ureter 
tumors the mean age of patients with mutated tumors 
was significantly higher than the mean age of patients 
with non-mutated tumors (72,4 years vs. 65,1 years). 
Although both cohorts showed a mean age typical for 
the regular onset of urothelial tumors the shift 
towards a lower TERT promoter frequency in an 
age-dependent manner is remarkable and also 
strengthens our findings. Interestingly, an 
age-dependent TERT promoter mutation frequency 
was also recently reported in papillary thyroid 
carcinoma. Liu and coworkers found a significant 
higher mutation frequency in patients aged >45 years 
compared to patients aged ≤45 years [16]. In addition, 
a study on medullablastomas reported TERT 
mutations to be significantly more frequent in an 
older cohort of pediatric patients (median age: 16 
years) compared to a very young patient cohort 
(median age: 6 years) [17]. All these data gave 
evidence for a minor role of TERT promoter mutation 
in tumors from patients with early-onset disease.  
It is difficult to explain this age-dependency. 
Focusing on bladder cancer it was recently shown that 
TERT promoter mutations lead to increased levels of 
TERT mRNA, TERT protein, telomerase enzymatic 
activity and telomere length in vitro [18]. Moreover, 
increased levels of TERT mRNA were shown to be 
associated with a reduced disease-specific survival 
suggesting high levels of TERT mRNA as a marker for 
biological aggressiveness in bladder cancer [18]. Our 
findings of a low TERT promoter mutation frequency 
in bladder tumors from young patients fits well with 
this observation as bladder tumors in young patients 
showed a low biological aggressiveness, and patients 
with early-onset disease displayed a favorable course 
of disease in most cases investigated [19, 20].  
 
 
Figure 2: Representative examples of TERT promoter mutations detected in bladder tumors using Sanger sequencing or SNaPshot analysis. A: Electropherograms 
of Sanger sequencing results for a -124 “G > A” mutant sample. B: SNaPshot profiles for wildtype, -124 “G > A” mutant and -146 “G > A” mutant samples. Arrows 
indicate mutant peaks. 
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Figure 3: Distribution of TERT promoter mutations in the early-onset and consecutive bladder cancer cohorts. 
 
 
Figure 4: Distribution of TERT promoter mutations within the early-onset bladder cancer cohort stratified according to median age. 
 
TERT promoter mutations were described as 
being frequently concomitant with FGFR3 mutations 
in bladder tumors especially in tumors with low 
grade and low stage [21]. Based on the limited 
molecular data available on early-onset bladder 
tumors FGFR3 mutation is a rare event in bladder 
tumors from young adults [22, 23]. As FGFR3 and 
TERT promoter mutations are the most frequent 
alterations in bladder cancer the low frequency of 
both mutations in tumors from patients with 
early-onset disease argues for a specific and discrete 
molecular background of tumorigenesis in these 
patients. In addition, in 4.2% of the tumors from the 
early-onset tumor cohort we detected a double 
mutation at positions -124 and -146 (Table 2). In 
contrast, in our consecutive cohort as well as in 
published cohorts mutations at these positions were 
found as being mutually exclusive [4, 5]. One 
explanation for this finding might be a possible 
molecular heterogeneity of the tumors, i.e. two 
separate clones within the sample each with a 
different mutation. A second explanation might be an 
acquired second mutation during the progress of 
malignant transformation. This second TERT 
mutation might be a rare event and possibly speed up 
a carcinogenic process. As a methodological proof of 
this concept is difficult this suggestion remains 
speculative but would be in favor of an exclusive 
molecular feature of tumors from young patients. Our 
own studies on epigenetic changes in bladder tumors 
underlined a discrete molecular background in these 
cases as patients below 19 years of age showed a low 
rate of epigenetic alterations compared to elderly 
patients [24]. 
This first report on TERT promoter mutations in 
bladder tumors from a large cohort of patients with 
early-onset disease has shown that these tumors have 
a lower mutation frequency as compared to that 
reported in patients with regular disease-onset. These 
data further strengthen the suggestion of a distinct 
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molecular tumorigenesis in young bladder cancer 
patients. 
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